BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions
Latest Information Update: 25 Sep 2024
At a glance
- Drugs BR-55 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Bracco Diagnostics
Most Recent Events
- 19 Sep 2024 Status changed from active, no longer recruiting to discontinued. ( Sponsor decision; expiration of available study agent due to long recruitment timeline. )
- 31 Jul 2023 Planned End Date changed from 1 Jan 2022 to 31 Dec 2023.
- 31 Jul 2023 Status changed from completed to active, no longer recruiting.